Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder After Surgical Management

NCT00343356 is registered in ClinicalTrials.gov with LanZhou University as lead sponsor.

NCT NCT00343356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00343356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder After Surgical Management
Lead sponsor
LanZhou University
Phase
Phase 2
Overall status
Completed
Start date
June 30, 1996
Completion date
July 31, 2003
Enrollment
138
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bladder neoplasms